Status:
RECRUITING
Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer
Lead Sponsor:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Conditions:
Breast Cancer, Familial Male
Radiotherapy; Complications
Eligibility:
FEMALE
18-70 years
Phase:
NA
Brief Summary
Radiation therapy is a crucial part in the comprehensive treatment of breast cancer. In recent years, emerging systemic treatment regimens such as HER 2 inhibitors, CDK 4/6 inhibitors, PARP inhibitors...
Eligibility Criteria
Inclusion
- ECOG 0-2. Aged 18-70 years old. Pathologically diagnosed as breast cancer. Need to receive radiotherapy according to guidelines. Radiotherapy target volume included chest wall/breast with or without lymph node regions.
- Need to receive one of the following therapies according to guidelines, capetabine, CDK4/6 inhibitor, PARP inhibitor , ICIs , HER2 inhibitors.
Exclusion
- Male breast cancer. Allergy to the upper medicines before. Will receive trastuzumab alone during and/or after radiotherapy. With severe other disease.
Key Trial Info
Start Date :
January 12 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 15 2027
Estimated Enrollment :
148 Patients enrolled
Trial Details
Trial ID
NCT06197581
Start Date
January 12 2024
End Date
January 15 2027
Last Update
August 21 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cancer Hospital ,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, Beijing Municipality, China, 100021